HDAC5 deficiency induces intrinsic resistance to KRAS inhibition by disrupting c-Myc acetylation-ubiquitination homeostasis
Journal of Clinical Investigation · 02.02.2026 · 136 (3)
DOI: 10.1172/jci195814 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 11.12.2025. Verfasst von Taoyu Chen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreatic Surgery. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Proto-Oncogene Proteins c-myc, Ubiquitination, Histone Deacetylases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese National Natural Science Foundation Grant, Hubei Province Natural Science Foundation.
Abstract (Originalsprache)
KRAS mutations serve as key oncogenic drivers in the initiation and progression of pancreatic ductal adenocarcinoma (PDAC). Despite the advancement of KRAS inhibitors, such as MRTX1133, for PDAC treatment, intrinsic and acquired resistance remain major barriers to their clinical efficacy. This study underscored the role of histone deacetylase 5 (HDAC5) loss in mediating intrinsic resistance to KRAS G12D inhibitors. Mechanistically, HDAC5 promoted c-Myc degradation by deacetylating K148, thereby facilitating NEDD4-mediated ubiquitination at this site. The loss of HDAC5 resulted in hyperacetylation of c-Myc at K148, impeding the ubiquitination and subsequent degradation process of c-Myc following deacetylation. Consequently, c-Myc stability and transcriptional activity were sustained even under KRAS/MEK/ERK pathway inhibition, reinforcing MAPK signaling and promoting cell survival despite KRAS suppression. Our data further demonstrated that pharmacological or genetic inhibition of c-Myc effectively reversed the resistance phenotype mediated by HDAC5 loss, suggesting a therapeutic strategy centered on KRAS-MYC dual-node blockade. Furthermore, the expression levels of HDAC5 and the acetylation status of c-Myc may serve as biomarkers for predicting the therapeutic response to MRTX1133. These findings provide insights into overcoming resistance to KRAS G12D inhibitors and offer potential biomarkers and combinatorial therapeutic strategies for precision treatment of PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pancreatic Surgery.
- Sino-German Laboratory of Personalized Medicine for Pancreatic Cancer.
- Cancer Center.
- Department of Urology, and.
- Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Förderung
- Chinese National Natural Science Foundation Grant
- Hubei Province Natural Science Foundation
Zitieren
APA
Chen, T., Yu, H., Wang, K., Qin, G., Zhao, Y., Liang, X., Li, Y., Zou, T., Liu, J., Zhao, J., Liu, Z., Wei, R., Wang, B., Gou, S., Yin, T., Wu, H., Jin, X., & Zhou, Y. (2026). HDAC5 deficiency induces intrinsic resistance to KRAS inhibition by disrupting c-Myc acetylation-ubiquitination homeostasis. Journal of Clinical Investigation, 136(3). https://doi.org/10.1172/jci195814
Vancouver
Chen T, Yu H, Wang K, Qin G, Zhao Y, Liang X, et al. HDAC5 deficiency induces intrinsic resistance to KRAS inhibition by disrupting c-Myc acetylation-ubiquitination homeostasis. Journal of Clinical Investigation. 2026;136(3). doi:10.1172/jci195814
BibTeX
@article{Chen2026,
author = {Chen, Taoyu and Yu, Haixin and Wang, Keshan and Qin, Gengdu and Zhao, Yuhan and Liang, Xueyi and Li, Yuxuan and Zou, Tianhao and Liu, Jiaying and Zhao, Jingyuan and Liu, Zhiqiang and Wei, Ruozheng and Wang, Bo and Gou, Shanmiao and Yin, Tao and Wu, Heshui and Jin, Xin and Zhou, Yingke},
title = {HDAC5 deficiency induces intrinsic resistance to KRAS inhibition by disrupting c-Myc acetylation-ubiquitination homeostasis},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {3},
doi = {10.1172/jci195814}
}
EUVIMED